Advicor: profile and news

Romney Hires Former Bush Campaign Advicor Feb 24, 2006
Sally Canfield, currently policy adviser to House Speaker Dennis Hastert, will move to Boston and join the payroll of Romney's political action committee in mid ... - Hub Politics,

Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006
The Company currently markets Niaspan and Advicor(R) for the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem LA for the ... - Genetic Engineering News,

Kos Announces Presentation at the Lehman Brothers Ninth Annual ... Mar 1, 2006
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News,

Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006
...to generate enhanced revenue andearnings, achieve its financial projections for 2006 and 2007,continue to grow sales of Niaspan, Advicor, Azmacort, Cardizem LA ... - Finanzen.net,

Kos Reports Summary Results of Key Phase IV Research and ... Feb 23, 2006
...by the Company's patents and those related to theacquired and licensed products, the ability to build awareness forNiaspan, Advicor, Azmacort, Cardizem LA ... - Finanzen.net,

Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006
...agreement with Teva, as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and Advicor(R) cholesterol ... - MSN Money

Low-Carb 'Dear Abby' Answers Your Questions Feb 17, 2006
My internist put me on Advicor (a statin drug) due to my HDL being 39, triglycerides at 130, total cholesterol at 235 and LDL at 175. ... - The Common Voice,

Kos Announces Presentation at the Deutsche Bank Small Cap Growth ... Feb 6, 2006
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Business Wire (press release),

Studies: Statins Don't Cut Risk of Colon, Other Cancers Jan 9, 2006
The specific statins studied included atorvastatin (Lipitor, Caduet), cerivastatin (Baycol), fluvastatin (Lescol), lovastatin (Advicor, Altoprev, Mevacor ... - ACS News Center,

Kos Reports on Promising Data Presented at AHA: New Compound ... Nov 14, 2005
..."We are proud of our pioneering developments in the cholesterol market, specifically with Niaspan(R) and Advicor(R), highly differentiated products aimed at ... - Genetic Engineering News,

Kos Reports on Promising Data Presented at AHA: New Compound ... Nov 14, 2005
..."We are proud of our pioneering developments in the cholesterolmarket, specifically with Niaspan(R) and Advicor(R), highlydifferentiated products aimed at ... - Finanzen.net,

StreetNotes: A Daily Roundup of Street Research Nov 30, 2005
Hold rating. The company is well positioned, offering a portfolio of therapies targeting HDL, namely Niaspan and Advicor. INCO downgraded ... - TheStreet.com

Kos Reports on New Research Presented at AHA: Raising HDL-C or '' ... Nov 15, 2005
This kind of heightened awareness and recognition bodes extremely well for Kos' highly differentiated Niaspan and Advicor(R) products in what is a vastly ... - Business Wire (press release),

Upgrade boosts Kos Pharmaceuticals stock Nov 22, 2005
Commission. The settlement allows Barr to manufacture generic Niaspan and Advicor, another cholesterol drug, in exchange for royalties. ... - BusinessWeek

Kos Reports on New Research Presented at AHA: Raising Hdl-c or “ ... Nov 16, 2005
...activities. The Company currently markets Niaspan ® , Advicor ® , Azmacort ® , Cardizem ® LA , Teveten ® , and Teveten ® HCT. ... - PharmaLive.com (press release),

Duramed Completes Acquisition of FEI Women's Health and ParaGard(R ... Nov 10, 2005
In addition to ParaGard(R), the Specialty Sales Force will detail Niaspan(R) and Advicor(R) under the Company's agreements with Kos Pharmaceuticals, Inc., as ... - PR Newswire (press release),

Kos Reports on New Research Presented at AHA: Raising HDL-C or '' ... Nov 15, 2005
...activities. The Company currentlymarkets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R) LA,Teveten(R), and Teveten(R) HCT. Kos ... - Finanzen.net,

Duramed Completes Acquisition of FEI Women's Health and ParaGard(R ... Nov 10, 2005
In addition to ParaGard®, the Specialty Sales Force will detail Niaspan® and Advicor® under the Company's agreements with Kos Pharmaceuticals, Inc., as well ... - Yahoo! News (press release)

Kos Paying Jerini $27M For US Icatibant Rights Nov 7, 2005
...to a record $205.1 million, up from $131.9 million for the third quarter of 2004, thanks to growth of the cholesterol products Niaspan and Advicor, as well as ... - BioWorld Online (subscription),

Kos Pharmaceuticals To Report Third Quarter Results On November 3 ... Oct 6, 2005
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News,

Doubling up in battle to beat cholesterol Aug 26, 2005
It also appears to be more potent than currently available combinations such as Advicor and the pipeline drug KS-01-019 (simvastatin + Niaspan) which are ... - Pharmaceutical Business Review

UPDATE 1-Kos Pharma profit better than expected, sales jump Aug 4, 2005
Revenue jumped 49 percent to $179 million, fueled by increased demand for the cholesterol drugs Niaspan and Advicor and asthma treatment Azmacort, a product ... - Reuters

Kos Posts Better-Than-Expected 2Q Profit Aug 4, 2005
...increased 49 percent to $179.4 million from $120.3 million, boosted by strong sales and prescription growth of Kos' cholesterol products, Niaspan and Advicor. ... - Forbes

Kos Pharmaceuticals to Report Second Quarter Results on August 4 ... Jul 7, 2005
The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - dBusinessNews Newark (press release)

Kos Pharmaceuticals Announces Commencement of Landmark Long-Term ... Jul 5, 2005
The Company currently markets Niaspan and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the ... - Business Wire (press release)

Kos Pharmaceuticals: Niaspan combination could offer another ... Jul 7, 2005
Furthermore, realizing that patients are often prescribed Niaspan alongside a statin, Kos launched Advicor, a lovastatin plus niacin combination, in 2002. ... - Pharmaceutical Business Review <**results**>